Indications
Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Composition
- Active substance
- insulin aspart
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Insulin aspart Sanofi
- Active substance
- insulin aspart
- ATC code
- A10AB05
- Therapeutic area
- Diabetes Mellitus
- Marketing authorisation holder
- Sanofi Winthrop Industrie
- Status
- Authorised
- EU authorisation
- 25 Jun 2020